Sanford-Burnham News Archive

Sanford-Burnham Medical Research Institute Appoints New Business Development Executive

ORLANDO, Fla. , September 8, 2010

Leslie Molony, Ph.D. has joined Sanford-Burnham Medical Research Institute as Senior Director, Business Development. Dr. Molony will lead the Institute’s activities to develop and implement strategies for establishing new collaborations, licensing technology, and spinning off companies based on research coming out of the Institute with an emphasis on activity at the Lake Nona site in Orlando, Florida. She will be based at the Lake Nona site.  The appointment of Dr. Molony emphasizes the Institute’s bi-coastal focus on maximizing the impact of its research by translating its laboratory discoveries and technologies into therapeutics and commercial applications.

Dr. Molony’s science background and industry experience in both drug discovery and business development will be integral to the Institute’s business development team. Dr. Molony received both her B.S. (Physics) and Ph.D. (Anatomy/Cell Biology) degrees from Duke Univer¬sity, and completed postdoctoral studies at the University of North Carolina. She completed course work for the Certificate in Financial Management at the University of California, San Diego. As a business development consultant, she has worked with global firms including EBD Group, ProPharma Partners, and Recombinant Capital. Prior to joining Sanford-Burnham, Dr. Molony was President, CEO & Director of Transgeneron Therapeutics, Inc. in Gainesville, Florida. She is the founder of RiverWood BioConsulting through which she served as Business Development Principal for Sunesis Pharmaceuticals, Inc., SVP Business Development for Nanotherapeutics, Inc. and Interim CEO of St Charles Pharmaceuticals.

“Dr. Molony has a track record that demonstrates her strong business acumen, including many successful licensing transactions and experience with company formation,” said Paul Laikind, Ph.D., Senior Vice President, Business Development and Chief Business Officer. “Her entrepreneurial spirit, and well-developed industry relationships will help us to maximize the impact of Institute research.” Dr. Laikind leads Sanford-Burnham’s business development activities on an international basis to strategically evaluate and leverage the Institute’s research.
Dr. Molony will also serve as a spokesperson and Institute representative for Florida’s biotech community. “We are thrilled that Dr. Molony will be joining Sanford-Burnham and our Lake Nona Medical City partners as we create a vibrant cluster of life sciences innovation and commercialization in Central Florida,” said Thad Seymour, Vice President and General Manager, Health and Life Science Investments, Lake Nona Holdings.

About Sanford-Burnham Medical Research Institute

Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham takes a collaborative approach to medical research with major programs in cancer, neurodegeneration and stem cells, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is recognized for its National Cancer Institute-designated Cancer Center and expertise in drug discovery technologies. Sanford-Burnham is a nonprofit, independent institute that employs more than 1,000 scientists and staff in San Diego (La Jolla), Calif., and Orlando (Lake Nona), Fla. For more information, visit us at

Sanford-Burnham can also be found on Facebook at and on Twitter @sanfordburnham.

News & News and Press - Sanford-Burnham Boilerplate
Sign In Skip Navigation Links Skip navigation links
News Archive
Sanford-Burnham In The News
Media Contacts and Guidelines
News Search
Paper of the Week
Quarterly Science Highlights
Multimedia Resources